Zogenix initiated at Northland

Zogenix initiated with an Outperform at Northland. analyst Carl Byrnes initiated Zogenix with an Outperform and $70 price target saying ZX008 is positioned to emerge as the 1st-line adjunctive therapy for patients with Dravet syndrome, achieving high market penetration. Byrnes is forecasting peak us US sales from the Dravet syndrome indication of $225M, with peak global sales for the indication at $500MM. Importantly, ZX008 has peak global sales potential greater than $2B, inclusive of other epileptic indications, the analyst wrote in a note to investors.
https://thefly.com/landingPageNews.php?id=2789281